Koers Laboratorio Reig Jofre SA BME
Aandelen
ES0165359011
Farmaceutische producten
slotkoers
Andere beurzen
|
||
- EUR | - |
10/05 | Laboratorio Reig Jofre, S.A. rapporteert resultaten voor het eerste kwartaal eindigend op 31 maart 2024 | CI |
13/03 | Transcript : Laboratorio Reig Jofre, S.A., 2023 Earnings Call, Mar 13, 2024 |
Omzet 2024 * | 349 mln. 373 mln. | Omzet 2025 * | 379 mln. 406 mln. | Marktkapitalisatie | 221 mln. 236 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 11 mln. 11,77 mln. | Nettowinst (verlies) 2025 * | 14 mln. 14,99 mln. | EV/omzet 2024 * | 0,75 x |
Nettoschuld 2024 * | 39,5 mln. 42,28 mln. | Nettoschuld 2025 * | 33,3 mln. 35,64 mln. | EV/omzet 2025 * | 0,67 x |
K/w-verhouding 2024 * |
20,1
x | K/w-verhouding 2025 * |
15,7
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 21,19% |
Recentste transcriptie over Laboratorio Reig Jofre SA
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 56 | 01-01-06 | |
Carmen Esclapés
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-03 |
Chief Operating Officer | 52 | 01-01-03 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 56 | 01-01-06 | |
Director/Board Member | - | 31-12-14 | |
Director/Board Member | - | 31-12-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+55,29% | 811 mld. | |
+43,62% | 640 mld. | |
-7,11% | 353 mld. | |
+18,98% | 333 mld. | |
+9,08% | 302 mld. | |
+16,30% | 246 mld. | |
+2,41% | 225 mld. | |
+12,47% | 218 mld. | |
+8,47% | 168 mld. |